The Parkinson Progression Marker Initiative (PPMI)

Kenneth Marek; Danna Jennings; Shirley Lasch; Andrew Siderowf; Caroline Tanner; Tanya Simuni; Chris Coffey; Karl Kieburtz; Emily Flagg; Sohini Chowdhury; Werner Poewe; Brit Mollenhauer; Todd Sherer; Mark Frasier; Claire Meunier; Alice Rudolph; Cindy Casaceli; John Seibyl; Susan Mendick; Norbert Schuff; Ying Zhang; Arthur Toga; Karen Crawford; Alison Ansbach; Pasquale de Blasio; Michele Piovella; John Trojanowski; Les Shaw; Andrew Singleton; Keith Hawkins; Jamie Eberling; David Russell; Laura Leary; Stewart Factor; Barbara Sommerfeld; Penelope Hogarth; Emily Pighetti; Karen Williams; David Standaert; Stephanie Guthrie; Robert Hauser; Holly Delgado; Joseph Jankovic; Christine Hunter; Matthew Stern; Baochan Tran; Jim Leverenz; Marne Baca; Sam Frank; Cathi Ann Thomas; Irene Richard; Cheryl Deeley; Linda Rees; Fabienne Sprenger; Elisabeth Lang; Holly Shill; Sanja Obradov; Hubert Fernandez; Adrienna Winters; Daniela Berg; Katharina Gauss; Douglas Galasko; Deborah Fontaine; Zoltan Mari; Melissa Gerstenhaber; David Brooks; Sophie Malloy; Paolo Barone; Katia Longo; Tom Comery; Bernard Ravina; Igor Grachev; Kim Gallagher; Michelle Collins; Katherine L. Widnell; Suzanne Ostrowizki; Paulo Fontoura; F. Hoffmann La-Roche; Tony Ho; Johan Luthman; Marcel van der Brug; Alastair D. Reith; Peggy Taylor

doi:10.1016/j.pneurobio.2011.09.005

The Parkinson Progression Marker Initiative (PPMI)

Kenneth Marek, Danna Jennings, Shirley Lasch, Andrew Siderowf, Caroline Tanner, Tanya Simuni, Chris Coffey, Karl Kieburtz, Emily Flagg, Sohini Chowdhury, Werner Poewe, Brit Mollenhauer, Todd Sherer, Mark Frasier, Claire Meunier, Alice Rudolph, Cindy Casaceli, John Seibyl, Susan Mendick, Norbert SchuffYing Zhang, Arthur Toga, Karen Crawford, Alison Ansbach, Pasquale de Blasio, Michele Piovella, John Trojanowski, Les Shaw, Andrew Singleton, Keith Hawkins, Jamie Eberling, David Russell, Laura Leary, Stewart Factor, Barbara Sommerfeld, Penelope Hogarth, Emily Pighetti, Karen Williams, David Standaert, Stephanie Guthrie, Robert Hauser, Holly Delgado, Joseph Jankovic, Christine Hunter, Matthew Stern, Baochan Tran, Jim Leverenz, Marne Baca, Sam Frank, Cathi Ann Thomas, Irene Richard, Cheryl Deeley, Linda Rees, Fabienne Sprenger, Elisabeth Lang, Holly Shill, Sanja Obradov, Hubert Fernandez, Adrienna Winters, Daniela Berg, Katharina Gauss, Douglas Galasko, Deborah Fontaine, Zoltan Mari, Melissa Gerstenhaber, David Brooks, Sophie Malloy, Paolo Barone, Katia Longo, Tom Comery, Bernard Ravina, Igor Grachev, Kim Gallagher, Michelle Collins, Katherine L. Widnell, Suzanne Ostrowizki, Paulo Fontoura, F. Hoffmann La-Roche, Tony Ho, Johan Luthman, Marcel van der Brug, Alastair D. Reith, Peggy Taylor

Research output: Contribution to journal › Review article › peer-review

650 Scopus citations

Abstract

The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials. The PPMI cohort will comprise 400 recently diagnosed PD and 200 healthy subjects followed longitudinally for clinical, imaging and biospecimen biomarker assessment using standardized data acquisition protocols at twenty-one clinical sites. All study data will be integrated in the PPMI study database and will be rapidly and publically available through the PPMI web site- www.ppmi-info.org. Biological samples including longitudinal collection of blood, cerebrospinal fluid (CSF) and urine will be available to scientists by application to an independent PPMI biospecimen review committee also through the PPMI web site. PPMI will rely on a partnership of government, PD foundations, industry and academics working cooperatively. This approach is crucial to enhance the potential for success of this ambitious strategy to develop PD progression biomarkers that will accelerate research in disease modifying therapeutics.

Original language	English (US)
Pages (from-to)	629-635
Number of pages	7
Journal	Progress in Neurobiology
Volume	95
Issue number	4
DOIs	https://doi.org/10.1016/j.pneurobio.2011.09.005
State	Published - Dec 2011
Externally published	Yes

Keywords

Alpha synuclein
Biomarker
Cerebrospinal fluid
Diffusion tensor imaging
Dopamine transporter imaging

ASJC Scopus subject areas

General Neuroscience

Access to Document

10.1016/j.pneurobio.2011.09.005

Cite this

Marek, K., Jennings, D., Lasch, S., Siderowf, A., Tanner, C., Simuni, T., Coffey, C., Kieburtz, K., Flagg, E., Chowdhury, S., Poewe, W., Mollenhauer, B., Sherer, T., Frasier, M., Meunier, C., Rudolph, A., Casaceli, C., Seibyl, J., Mendick, S., ... Taylor, P. (2011). The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology, 95(4), 629-635. https://doi.org/10.1016/j.pneurobio.2011.09.005

Marek, K, Jennings, D, Lasch, S, Siderowf, A, Tanner, C, Simuni, T, Coffey, C, Kieburtz, K, Flagg, E, Chowdhury, S, Poewe, W, Mollenhauer, B, Sherer, T, Frasier, M, Meunier, C, Rudolph, A, Casaceli, C, Seibyl, J, Mendick, S, Schuff, N, Zhang, Y, Toga, A, Crawford, K, Ansbach, A, de Blasio, P, Piovella, M, Trojanowski, J, Shaw, L, Singleton, A, Hawkins, K, Eberling, J, Russell, D, Leary, L, Factor, S, Sommerfeld, B, Hogarth, P, Pighetti, E, Williams, K, Standaert, D, Guthrie, S, Hauser, R, Delgado, H, Jankovic, J, Hunter, C, Stern, M, Tran, B, Leverenz, J, Baca, M, Frank, S, Thomas, CA, Richard, I, Deeley, C, Rees, L, Sprenger, F, Lang, E, Shill, H, Obradov, S, Fernandez, H, Winters, A, Berg, D, Gauss, K, Galasko, D, Fontaine, D, Mari, Z, Gerstenhaber, M, Brooks, D, Malloy, S, Barone, P, Longo, K, Comery, T, Ravina, B, Grachev, I, Gallagher, K, Collins, M, Widnell, KL, Ostrowizki, S, Fontoura, P, La-Roche, FH, Ho, T, Luthman, J, van der Brug, M, Reith, AD & Taylor, P 2011, 'The Parkinson Progression Marker Initiative (PPMI)', Progress in Neurobiology, vol. 95, no. 4, pp. 629-635. https://doi.org/10.1016/j.pneurobio.2011.09.005

@article{f5d11b9e62be4663b6e7da9b903de275,

title = "The Parkinson Progression Marker Initiative (PPMI)",

abstract = "The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials. The PPMI cohort will comprise 400 recently diagnosed PD and 200 healthy subjects followed longitudinally for clinical, imaging and biospecimen biomarker assessment using standardized data acquisition protocols at twenty-one clinical sites. All study data will be integrated in the PPMI study database and will be rapidly and publically available through the PPMI web site- www.ppmi-info.org. Biological samples including longitudinal collection of blood, cerebrospinal fluid (CSF) and urine will be available to scientists by application to an independent PPMI biospecimen review committee also through the PPMI web site. PPMI will rely on a partnership of government, PD foundations, industry and academics working cooperatively. This approach is crucial to enhance the potential for success of this ambitious strategy to develop PD progression biomarkers that will accelerate research in disease modifying therapeutics.",

keywords = "Alpha synuclein, Biomarker, Cerebrospinal fluid, Diffusion tensor imaging, Dopamine transporter imaging",

author = "Kenneth Marek and Danna Jennings and Shirley Lasch and Andrew Siderowf and Caroline Tanner and Tanya Simuni and Chris Coffey and Karl Kieburtz and Emily Flagg and Sohini Chowdhury and Werner Poewe and Brit Mollenhauer and Todd Sherer and Mark Frasier and Claire Meunier and Alice Rudolph and Cindy Casaceli and John Seibyl and Susan Mendick and Norbert Schuff and Ying Zhang and Arthur Toga and Karen Crawford and Alison Ansbach and {de Blasio}, Pasquale and Michele Piovella and John Trojanowski and Les Shaw and Andrew Singleton and Keith Hawkins and Jamie Eberling and David Russell and Laura Leary and Stewart Factor and Barbara Sommerfeld and Penelope Hogarth and Emily Pighetti and Karen Williams and David Standaert and Stephanie Guthrie and Robert Hauser and Holly Delgado and Joseph Jankovic and Christine Hunter and Matthew Stern and Baochan Tran and Jim Leverenz and Marne Baca and Sam Frank and Thomas, {Cathi Ann} and Irene Richard and Cheryl Deeley and Linda Rees and Fabienne Sprenger and Elisabeth Lang and Holly Shill and Sanja Obradov and Hubert Fernandez and Adrienna Winters and Daniela Berg and Katharina Gauss and Douglas Galasko and Deborah Fontaine and Zoltan Mari and Melissa Gerstenhaber and David Brooks and Sophie Malloy and Paolo Barone and Katia Longo and Tom Comery and Bernard Ravina and Igor Grachev and Kim Gallagher and Michelle Collins and Widnell, {Katherine L.} and Suzanne Ostrowizki and Paulo Fontoura and La-Roche, {F. Hoffmann} and Tony Ho and Johan Luthman and {van der Brug}, Marcel and Reith, {Alastair D.} and Peggy Taylor",

note = "Funding Information: Reliable and well-validated biomarkers for Parkinson Disease (PD) progression would dramatically accelerate research into both PD etiology and therapeutics. During the past two decades much progress has been made in identifying and assessing PD biomarkers, but as yet no fully validated biomarker for PD is currently available ( Maetzler et al., 2009; Marek et al., 2008; Schapira, 2004; Olanow et al., 2008; Gerlach et al., 2008; Shi et al., 2009; Scherzer et al., 2007; Ravina et al., 2009 ). Given the recent advances in molecular genetics, neurobiology, and imaging technology and the recognition that the lack of PD biomarkers has created a roadblock for further studies of disease modifying therapies, a major initiative to develop PD biomarkers is both timely and necessary. Therefore, the Parkinson Progression Marker Initiative (PPMI), a collaborative effort of PD researchers with expertise in biomarker development, PD clinical study design and implementation, and bioinformatics, statistics, and data management, was developed to identify and validate PD progression markers ( The Lancet, 2010 ). PPMI is a public–private partnership, largely sponsored by the Michael J Fox Foundation with substantial industry partnership (GE Healthcare, Pfizer, Roche, Genentech, Merck, Abbott, Biogen, Covance, Glaxo-Smith-Kline). ",

year = "2011",

month = dec,

doi = "10.1016/j.pneurobio.2011.09.005",

language = "English (US)",

volume = "95",

pages = "629--635",

journal = "Progress in Neurobiology",

issn = "0301-0082",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - The Parkinson Progression Marker Initiative (PPMI)

AU - Marek, Kenneth

AU - Jennings, Danna

AU - Lasch, Shirley

AU - Siderowf, Andrew

AU - Tanner, Caroline

AU - Simuni, Tanya

AU - Coffey, Chris

AU - Kieburtz, Karl

AU - Flagg, Emily

AU - Chowdhury, Sohini

AU - Poewe, Werner

AU - Mollenhauer, Brit

AU - Sherer, Todd

AU - Frasier, Mark

AU - Meunier, Claire

AU - Rudolph, Alice

AU - Casaceli, Cindy

AU - Seibyl, John

AU - Mendick, Susan

AU - Schuff, Norbert

AU - Zhang, Ying

AU - Toga, Arthur

AU - Crawford, Karen

AU - Ansbach, Alison

AU - de Blasio, Pasquale

AU - Piovella, Michele

AU - Trojanowski, John

AU - Shaw, Les

AU - Singleton, Andrew

AU - Hawkins, Keith

AU - Eberling, Jamie

AU - Russell, David

AU - Leary, Laura

AU - Factor, Stewart

AU - Sommerfeld, Barbara

AU - Hogarth, Penelope

AU - Pighetti, Emily

AU - Williams, Karen

AU - Standaert, David

AU - Guthrie, Stephanie

AU - Hauser, Robert

AU - Delgado, Holly

AU - Jankovic, Joseph

AU - Hunter, Christine

AU - Stern, Matthew

AU - Tran, Baochan

AU - Leverenz, Jim

AU - Baca, Marne

AU - Frank, Sam

AU - Thomas, Cathi Ann

AU - Richard, Irene

AU - Deeley, Cheryl

AU - Rees, Linda

AU - Sprenger, Fabienne

AU - Lang, Elisabeth

AU - Shill, Holly

AU - Obradov, Sanja

AU - Fernandez, Hubert

AU - Winters, Adrienna

AU - Berg, Daniela

AU - Gauss, Katharina

AU - Galasko, Douglas

AU - Fontaine, Deborah

AU - Mari, Zoltan

AU - Gerstenhaber, Melissa

AU - Brooks, David

AU - Malloy, Sophie

AU - Barone, Paolo

AU - Longo, Katia

AU - Comery, Tom

AU - Ravina, Bernard

AU - Grachev, Igor

AU - Gallagher, Kim

AU - Collins, Michelle

AU - Widnell, Katherine L.

AU - Ostrowizki, Suzanne

AU - Fontoura, Paulo

AU - La-Roche, F. Hoffmann

AU - Ho, Tony

AU - Luthman, Johan

AU - van der Brug, Marcel

AU - Reith, Alastair D.

AU - Taylor, Peggy

N1 - Funding Information: Reliable and well-validated biomarkers for Parkinson Disease (PD) progression would dramatically accelerate research into both PD etiology and therapeutics. During the past two decades much progress has been made in identifying and assessing PD biomarkers, but as yet no fully validated biomarker for PD is currently available ( Maetzler et al., 2009; Marek et al., 2008; Schapira, 2004; Olanow et al., 2008; Gerlach et al., 2008; Shi et al., 2009; Scherzer et al., 2007; Ravina et al., 2009 ). Given the recent advances in molecular genetics, neurobiology, and imaging technology and the recognition that the lack of PD biomarkers has created a roadblock for further studies of disease modifying therapies, a major initiative to develop PD biomarkers is both timely and necessary. Therefore, the Parkinson Progression Marker Initiative (PPMI), a collaborative effort of PD researchers with expertise in biomarker development, PD clinical study design and implementation, and bioinformatics, statistics, and data management, was developed to identify and validate PD progression markers ( The Lancet, 2010 ). PPMI is a public–private partnership, largely sponsored by the Michael J Fox Foundation with substantial industry partnership (GE Healthcare, Pfizer, Roche, Genentech, Merck, Abbott, Biogen, Covance, Glaxo-Smith-Kline).

PY - 2011/12

Y1 - 2011/12

N2 - The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials. The PPMI cohort will comprise 400 recently diagnosed PD and 200 healthy subjects followed longitudinally for clinical, imaging and biospecimen biomarker assessment using standardized data acquisition protocols at twenty-one clinical sites. All study data will be integrated in the PPMI study database and will be rapidly and publically available through the PPMI web site- www.ppmi-info.org. Biological samples including longitudinal collection of blood, cerebrospinal fluid (CSF) and urine will be available to scientists by application to an independent PPMI biospecimen review committee also through the PPMI web site. PPMI will rely on a partnership of government, PD foundations, industry and academics working cooperatively. This approach is crucial to enhance the potential for success of this ambitious strategy to develop PD progression biomarkers that will accelerate research in disease modifying therapeutics.

AB - The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials. The PPMI cohort will comprise 400 recently diagnosed PD and 200 healthy subjects followed longitudinally for clinical, imaging and biospecimen biomarker assessment using standardized data acquisition protocols at twenty-one clinical sites. All study data will be integrated in the PPMI study database and will be rapidly and publically available through the PPMI web site- www.ppmi-info.org. Biological samples including longitudinal collection of blood, cerebrospinal fluid (CSF) and urine will be available to scientists by application to an independent PPMI biospecimen review committee also through the PPMI web site. PPMI will rely on a partnership of government, PD foundations, industry and academics working cooperatively. This approach is crucial to enhance the potential for success of this ambitious strategy to develop PD progression biomarkers that will accelerate research in disease modifying therapeutics.

KW - Alpha synuclein

KW - Biomarker

KW - Cerebrospinal fluid

KW - Diffusion tensor imaging

KW - Dopamine transporter imaging

UR - http://www.scopus.com/inward/record.url?scp=82755161902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82755161902&partnerID=8YFLogxK

U2 - 10.1016/j.pneurobio.2011.09.005

DO - 10.1016/j.pneurobio.2011.09.005

M3 - Review article

C2 - 21930184

AN - SCOPUS:82755161902

SN - 0301-0082

VL - 95

SP - 629

EP - 635

JO - Progress in Neurobiology

JF - Progress in Neurobiology

IS - 4

ER -

The Parkinson Progression Marker Initiative (PPMI)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this